tiprankstipranks
Trending News
More News >
Careteq Ltd. (AU:CTQ)
ASX:CTQ
Australian Market
Advertisement

Careteq Ltd. (CTQ) AI Stock Analysis

Compare
1 Followers

Top Page

AU:CTQ

Careteq Ltd.

(Sydney:CTQ)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
AU$0.01
▲(0.00% Upside)
Careteq Ltd. faces significant financial challenges, with high leverage and negative cash flows being the most impactful factors. Technical indicators suggest weak momentum, and valuation metrics are unattractive due to ongoing losses. The company needs to improve financial stability and profitability to enhance its stock attractiveness.
Positive Factors
Revenue Growth
The consistent revenue growth reflects Careteq's ability to expand its market reach and enhance product adoption, which is crucial for long-term success in the competitive healthcare technology sector.
Innovative Product Offering
Careteq's focus on digital health products like smart monitoring and telehealth services positions it well to capitalize on growing demand for advanced healthcare solutions, supporting sustainable growth.
Strategic Partnerships
By forming strategic partnerships with healthcare institutions and tech companies, Careteq can enhance its product offerings and expand its market presence, supporting long-term revenue growth and competitive positioning.
Negative Factors
High Leverage
High leverage can strain financial flexibility and increase risk, potentially impacting Careteq's ability to invest in growth opportunities or weather economic downturns, posing a long-term financial challenge.
Negative Cash Flow
Negative cash flow metrics highlight inefficiencies in cash generation, which could hinder Careteq's ability to sustain operations and invest in future growth, affecting its long-term financial health.
Profitability Concerns
Ongoing profitability challenges, as indicated by negative margins, suggest difficulties in cost management or pricing strategy, potentially impacting Careteq's ability to achieve sustainable financial performance.

Careteq Ltd. (CTQ) vs. iShares MSCI Australia ETF (EWA)

Careteq Ltd. Business Overview & Revenue Model

Company DescriptionCareteq Ltd. (CTQ) is a leading provider of innovative healthcare technology solutions, specializing in the development and deployment of digital health platforms and medical devices. The company operates primarily in the healthcare sector, focusing on improving patient outcomes through advanced telemedicine services, remote patient monitoring systems, and electronic health record management. With a commitment to enhancing the efficiency of healthcare delivery, Careteq Ltd. offers a suite of products designed for healthcare providers, patients, and caregivers, ensuring seamless communication and data accessibility.
How the Company Makes MoneyCareteq Ltd. generates revenue through multiple streams, including the sale of software licenses for its digital health platforms, subscription fees for ongoing services such as telemedicine and patient monitoring, and the sale of proprietary medical devices. The company also partners with healthcare institutions and insurance providers to integrate its solutions into existing systems, which provides additional revenue through service agreements and training programs. Moreover, Careteq Ltd. benefits from government grants and funding aimed at promoting digital health initiatives, further enhancing its financial sustainability.

Careteq Ltd. Financial Statement Overview

Summary
Careteq Ltd. demonstrates revenue growth but struggles with profitability and cash flow management. High leverage and negative equity returns pose financial risks, while negative cash flow metrics indicate challenges in sustaining operations.
Income Statement
45
Neutral
Careteq Ltd. shows a mixed performance in its income statement. The company has achieved revenue growth, with a 7.72% increase in the latest year, indicating a positive trajectory. However, profitability remains a concern, as evidenced by negative net profit margins and EBIT margins. The gross profit margin has significantly decreased from the previous year, reflecting challenges in cost management or pricing strategy.
Balance Sheet
40
Negative
The balance sheet reveals a high debt-to-equity ratio of 1.56, indicating significant leverage, which could pose financial risks. The return on equity is negative, reflecting ongoing losses. The equity ratio is relatively low, suggesting limited financial stability. These factors highlight potential risks in the company's financial structure.
Cash Flow
35
Negative
Careteq Ltd. faces challenges in cash flow management, with negative operating and free cash flows. The free cash flow growth rate is negative, indicating deteriorating cash generation capabilities. The operating cash flow to net income ratio is also negative, suggesting inefficiencies in converting income into cash.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue7.62M7.62M7.23M4.98M4.43M735.44K
Gross Profit1.50M1.50M6.74M-2.44M4.14M-2.03M
EBITDA275.62K275.62K-826.62K-2.65M-5.90M-5.06M
Net Income-72.20K-72.20K-2.67M-4.33M-5.25M-5.23M
Balance Sheet
Total Assets5.94M5.94M6.82M7.57M8.02M12.23M
Cash, Cash Equivalents and Short-Term Investments1.05M1.05M1.25M1.85M4.50M8.90M
Total Debt2.37M2.37M192.98K961.96K0.0075.28K
Total Liabilities4.42M4.42M3.30M4.02M1.72M2.61M
Stockholders Equity1.52M1.52M1.97M2.14M6.30M9.61M
Cash Flow
Free Cash Flow-804.93K-804.93K-2.59M-3.42M-4.54M-1.52M
Operating Cash Flow-732.06K-732.06K-1.30M-2.53M-4.52M-1.50M
Investing Cash Flow119.16K119.16K-570.80K-799.63K-256.83K-23.21K
Financing Cash Flow370.14K400.96K1.27M687.55K8.81M1.50M

Careteq Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.01
Negative
200DMA
0.01
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
36.48
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.48 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:CTQ.

Careteq Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
AU$63.69M-7.09-8647.54%25.98%22.10%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
41
Neutral
3.02%5.42%97.46%
41
Neutral
AU$6.16M-7.05-9.90%34.07%
40
Underperform
AU$16.45M-0.24-240.60%-48.41%-7200.00%
40
Underperform
AU$84.39M-11.89
34
Underperform
AU$10.99M-3.75241.34%44.19%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CTQ
Careteq Ltd.
0.01
0.00
0.00%
AU:GLH
Global Health Limited
0.09
-0.05
-35.71%
AU:MDR
MedAdvisor Limited
0.02
-0.28
-92.79%
AU:SHG
Singular Health Group Ltd
0.26
0.14
116.67%
AU:ICR
InteliCare Holdings Limited
0.02
0.01
100.00%
AU:PCK
PainChek Ltd
0.31
0.04
14.81%

Careteq Ltd. Corporate Events

Careteq Ltd. Releases 2025 Corporate Governance Statement
Aug 29, 2025

Careteq Ltd. has released its 2025 Corporate Governance Statement, detailing its adherence to the ASX Corporate Governance Principles and Recommendations. The company emphasizes its commitment to maintaining shareholder value, ethical conduct, and compliance with legal standards. The statement outlines the roles and responsibilities of the board and management, the company’s diversity policy, and the processes for evaluating the performance of the board and senior executives. This governance framework aims to strengthen Careteq’s operational integrity and stakeholder trust.

Careteq Limited Reports Financial Turnaround with Strategic Focus
Aug 29, 2025

Careteq Limited has reported a significant turnaround in its financial performance for FY25, achieving a group EBITDA profit from continuing operations of $0.3 million, compared to a loss in the previous year. This improvement is attributed to strategic decisions, including divesting the loss-making Sofihub business and acquiring the remaining stake in the profitable Embedded Health Solutions (EHS) unit. The company expects continued revenue growth and positive EBITDA in FY26, driven by synergies from integrating its platforms and partnerships with national GP networks.

Careteq Limited Reports Significant Reduction in Annual Loss
Aug 29, 2025

Careteq Limited reported a significant reduction in its loss for the year ended June 30, 2025, with a 97.3% decrease to $72,204 compared to the previous year. Despite a 7.1% decline in revenues, the company’s financial performance improved, reflecting effective cost management and strategic consolidation efforts, including the acquisition of Embedded Health Solutions Pty Ltd.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 17, 2025